• Sign In
  • FAQ
  • Create an Account
Currency
USD currency flagUSD
Toggle Nav
My Cart
Menu
Account
Settings
Currency
USD currency flagUSD

Raf

Shop By
Clear All

Items 1-50 of 123

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. A10001
    Sorafenib Tosylate (Nexavar)

    Raf inhibitor

    Sorafenib Tosylate (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
    Quick View
  2. A10002
    PLX-4720

    Raf inhibitor

    PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
    Quick View
  3. A10250
    Regorafenib (BAY 73-4506)

    VEGFR inhibitor

    Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
    Quick View
  4. A10420
    GDC-0879

    B-Raf inhibitor

    GDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
    Quick View
  5. A10661
    NVP-BHG712

    EphB4 inhibitor

    NVP-BHG712 is a selective inhibitor of EphB4 kinase that exhibits selectivity for EphB4 over more than 40 other kinases in vitro, including FGFR3.
    Quick View
  6. A13226
    LGX 818 (Encorafenib)

    Selective B-RAF Inhibitor

    LGX818 is an orally available Raf kinase inhibitor with potential antineoplastic activity.
    Quick View
  7. A11381
    Dabrafenib (GSK2118436A)

    Raf inhibitor

    Dabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
    Quick View
  8. A16079
    (E/Z)-Locostatin ((E/Z)-UIC-1005)

    RKIP/Raf1 inhibitor

    Locostatin is a cell permeable, potent inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.
    Quick View
  9. A10739
    PLX4032 (Vemurafenib)

    Raf inhibitor

    PLX4032 (Vemurafenib) also known as RG7204, Vemurafenib, R7204; RO5185426. PLX4032 is a B-raf inhibitor with an IC50 of 44 nM.
    Quick View
  10. A13323
    TAK-632

    pan-RAF inhibitor

    TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A375) IC50, 12 nM; pMEK (HMVII), 49 nM; V/B ratio.
    Quick View
  11. A14019
    Avutometinib (RO5126766, CH5126766)

    Raf/MEK dual inhibitor

    Avutometinib (RO5126766, CH5126766), is a protein kinase inhibitor specific for the Raf and MEK mitogen-activated protein kinases (MAPKs) with potential anti-neoplastic activity.

    Quick View
  12. A10773
    RAF265 (CHIR-265)

    RAF/VEGFR Inhibitor

    RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor, which is to control or normalize VEGFR-2 along with the inhibition of B-raf and c-Raf mutation to prevent cancers.
    Quick View
  13. A10774
    Raf265 derivative

    RAF/VEGFR Inhibitor

    Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.
    Quick View
  14. A10829
    SB590885

    B-Raf Inhibitor

    SB590885 is a selective small-molecule inhibitor of the B-Raf kinase and Ki app values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively.
    Quick View
  15. A11063
    AZ628

    Raf inhibitor

    AZ628 is a RAF inhibitor with IC50 values: ca 30 nM for BRAF V600E and wild-type CRAF and 100 nM for wild-type BRAF.
    Quick View
  16. A11077
    ZM 336372

    C-Raf inhibitor

    ZM 336372 is a potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells.
    Quick View
  17. A21834
    B-Raf inhibitor 1 dihydrochloride

    Raf kinase inhibitor

    B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively.
    Quick View
  18. A22317
    MCP110

    Ras/Raf-1 interaction inhibitor

    MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors.
    Quick View
  19. A22372
    CCT196969

    pan-Raf inhibitor

    CCT196969 is a pan-Raf inhibitor, which inhibits B-Raf, BRafV600E and CRAF with IC50s of 0.1, 0.04, and 0.01 μM, respectively.
    Quick View
  20. A20988
    rel-Lifirafenib

    Raf/EGFR inhibitor

    Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
    Quick View
  21. A21055
    B-Raf IN 1

    B-Raf kinase inhibitor

    B-Raf IN 1 is a potent and selective B-Raf kinase inhibitor with an IC50 of 24 nM.
    Quick View
  22. A21489
    Sorafenib (D3)

    Raf/VEGFR3 inhibitor

    Sorafenib D3 (Bay 43-9006 D3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Quick View
  23. A21495
    Sorafenib (D4)

    Raf/VEGFR3 inhibitor

    Sorafenib D4 (Bay 43-9006 D4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Quick View
  24. A22641
    Raf inhibitor 2

    raf kinase inhibitor

    Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research.
    Quick View
  25. A24810
    Norartocarpetin

    Tyrosinase Inhibitor

    Norartocarpetin is a potent tyrosinase inhibitor, demonstrating significant inhibition with an IC50 value of 0.47 μM. This compound serves as an effective antibrowning agent for food systems research and exhibits notable anticancer activity against lung carcinoma cells (NCI-H460) with an IC50 of 22 μM. Its antiproliferative effects are mediated through targeting the Ras/Raf/MAPK signaling pathway, inducing mitochondrial-mediated apoptosis, causing S-phase cell cycle arrest, and inhibiting cell migration and invasion in human lung carcinoma cells.
    Quick View
  26. A25316
    MO-2097

    RAF-1/HIF-1α Inhibitor

    MO-2097 is a selective RAF-1 and HIF-1α inhibitor that induces the destabilization of RAF-1, resulting in decreased levels of epithelial-mesenchymal transition (EMT) transcription factors and mesenchymal markers. Additionally, MO-2097 effectively inhibits HIF-1α protein expression mediated by hnRNPA2B1 in hypoxic conditions. This compound promotes the generation of mitochondrial reactive oxygen species (ROS), contributing to apoptosis in malignant cells. MO-2097 demonstrates significant potential in suppressing colorectal cancer metastasis by targeting the RAF/MEK/ERK signaling pathway and has shown efficacy in reducing tumor growth in HCT116 cell xenograft mouse models, thus serving as a valuable tool for colorectal cancer research.
    Quick View
  27. A25635
    Erufosine

    PI3K/Akt/Ras/Raf/MAPK Inhibitor

    Erufosine is a potent inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It demonstrates significant cytotoxic activity against breast cancer cell lines, specifically MCF-7 and MDA-MB-231, with IC50 values of 40.95 μM and 40.8 μM, respectively. By reducing the phosphorylation levels of PI3K (p85), Akt (PKB), and cRaf, Erufosine serves as a valuable tool in the research of breast cancer and myeloid leukemia.
    Quick View
  28. A26067
    PHI-501

    RAF/DDR Inhibitor

    PHI-501 is a dual inhibitor targeting RAF and DDR pathways. It demonstrates potent anti-proliferative effects in melanoma cell lines, effectively inhibiting colony formation in drug-resistant cells. PHI-501 disrupts ERK and AKT phosphorylation and downregulates key gene sets associated with TNFA-NFKB, IL6-JAK-STAT3, and KRAS signaling pathways, as well as pathways involved in epithelial-mesenchymal transition. In vivo studies show significant anti-tumor efficacy in the SK-MEL3DR xenograft model, making PHI-501 valuable for research on drug resistance in melanoma.
    Quick View
  29. A28558
    Lifirafenib maleate

    Raf/EGFR Inhibitor

    Lifirafenib maleate is a potent inhibitor of Raf kinase and EGFR, exhibiting IC50 values of 23 nM and 29 nM for recombinant BRafV600E and EGFR, respectively. This compound effectively disrupts critical signaling pathways involved in cancer cell proliferation and survival. Lifirafenib maleate is relevant for research applications in cancer biology, particularly in studies focusing on targeted therapies for tumors with BRAF mutations or EGFR dysregulation.
    Quick View
  30. A28755
    EGFR/BRAF-IN-1

    EGFR/BRAF Inhibitor

    EGFR/BRAF-IN-1 is a selective inhibitor targeting both EGFR and BRAFV600E with an IC50 of 45 nM. This compound, a 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivative, effectively inhibits cancer cell proliferation with a GI50 of 35 nM. Additionally, EGFR/BRAF-IN-1 exhibits notable antioxidant properties, making it a valuable reagent for research in cancer biology and therapeutic development.
    Quick View
  31. A12739
    PF-04880594

    RAF inhibitor

    PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively.
    Quick View
  32. A12891
    Diazepinomicin

    RAS/RAF/MAPK inhibitor

    Diazepinomicin, also known as TLN-4601, is a small-molecule inhibitor of the RAS/RAF/MAPK signaling pathway with potential antineoplastic activity.
    Quick View
  33. A13119
    Balamapimod (MKI-833)

    Ras/Raf/MEK inhibitor

    Balamapimod, also known as MKI-822, is a Ras/Raf/MEK inhibitor.
    Quick View
  34. A13177
    Belvarafenib

    pan RAF inhibitor

    Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
    Quick View
  35. A13525
    L-779450

    Raf inhibitor

    L-779450 is a raf kinase inhibitor, a potential treatment for neurotraumatic diseases.
    Quick View
  36. A13772
    CEP-32496

    Raf inhibitor

    CEP-32496 is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity.
    Quick View
  37. A14122
    B-Raf-inhibitor 1

    B-Raf inhibitor

    B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respectively
    Quick View
  38. A17225
    AZ304

    dual BRAF inhibitor

    AZ304 is a potent dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF. AZ304 exerted potent inhibitory effects on both wild type and V600E mutant forms of the serine/threonine-protein kinase BRAF, with IC50 values of 79?nM and 38?nM, respectively.
    Quick View
  39. A17857
    Sorafenib

    Raf/VEGFR3 inhibitor

    Sorafenib (Bay 43-9006) is a potent, orally active multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Quick View
  40. A19734
    BI-882370

    RAF inhibitor

    BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase.
    Quick View
  41. A19011
    RAF mutant-IN-1

    Raf nhibitor

    RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF340D/Y341D, B-RAFV600E and B-RAFWT, respectively.
    Quick View
  42. A19080
    Rineterkib (ERK-IN-1)

    RAF/ERK1/2 inhibitor

    Rineterkib (ERK-IN-1) (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.

    Quick View
  43. A19332
    AD80

    RET/RAF/SRC/S6K inhibitor

    AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
    Quick View
  44. A19449
    LUT014

    B-Raf inhibitor

    LUT014 is a B-Raf inhibitor with an IC50 of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 .
    Quick View
  45. A15040
    CEP-32496 hydrochloride

    Raf Inhibitor

    CEP-32496 hydrochloride is a highly potent inhibitor of wild-type BRAF, V600E mutant BRAF and c-Raf with Kd values of 14 nM, 36 nM and 39 nM, respectively.
    Quick View
  46. A15059
    Dabrafenib Mesylate

    Raf inhibitor

    Dabrafenib Mesylate is a novel, potent, and selective Raf kinase inhibitor that is capableof inhibiting the kinase activity of wild-type B-Raf, B-RafV600Eand c-Raf with IC50 values of 3.2, 0.8, and 5.0 nM, respectively.
    Quick View
  47. A15218
    Regorafenib monohydrate

    Tyrosine kinase inhibitor

    Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
    Quick View
  48. A11211
    ML 786 dihydrochloride

    Raf inhibitor

    ML 786 dihydrochloride is a potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively).
    Quick View
  49. A11240
    MLN2480 (BIIB-024)

    pan-Raf inhibitor

    MLN 2480 is an oral, selective pan-Raf kinase inhibitor in chinical trials.
    Quick View
  50. A11333
    BRAF inhibitor

    BRAF inhibitor

    BRAF inhibitor is a potent BRAF inhibitor.
    Quick View

Items 1-50 of 123

Page
per page
Set Descending Direction
Shop By
Now Shopping by
  1. Actions
    Inhibitor
Clear All
Shopping Options